Puma Biotechnology Inc (PBYI)
4.935
-0.14
(-2.66%)
USD |
NASDAQ |
May 01, 16:00
4.925
-0.01
(-0.20%)
After-Hours: 20:00
Puma Biotechnology Revenue (Quarterly): 72.18M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 72.18M |
September 30, 2023 | 56.12M |
June 30, 2023 | 54.57M |
March 31, 2023 | 52.78M |
December 31, 2022 | 65.68M |
September 30, 2022 | 57.10M |
June 30, 2022 | 59.52M |
March 31, 2022 | 45.74M |
December 31, 2021 | 55.36M |
September 30, 2021 | 46.24M |
June 30, 2021 | 53.38M |
March 31, 2021 | 98.17M |
December 31, 2020 | 52.56M |
Date | Value |
---|---|
September 30, 2020 | 50.75M |
June 30, 2020 | 70.58M |
March 31, 2020 | 51.22M |
December 31, 2019 | 62.92M |
September 30, 2019 | 56.35M |
June 30, 2019 | 53.92M |
March 31, 2019 | 99.07M |
December 31, 2018 | 71.08M |
September 30, 2018 | 62.63M |
June 30, 2018 | 50.77M |
March 31, 2018 | 66.52M |
December 31, 2017 | 21.61M |
September 30, 2017 | 6.077M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
45.74M
Minimum
Mar 2022
98.17M
Maximum
Mar 2021
58.69M
Average
55.36M
Median
Dec 2021
Revenue (Quarterly) Benchmarks
ADMA Biologics Inc | 73.90M |
Pfizer Inc | 14.25B |
Sarepta Therapeutics Inc | 396.78M |
Immunogen Inc (DELISTED) | 113.42M |
Regeneron Pharmaceuticals Inc | 3.434B |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 12.27M |
Total Expenses (Quarterly) | 57.38M |
EPS Diluted (Quarterly) | 0.25 |
Enterprise Value | 241.62M |
Gross Profit Margin (Quarterly) | 66.30% |
Profit Margin (Quarterly) | 17.00% |
Earnings Yield | 9.12% |
Operating Earnings Yield | 14.18% |
Normalized Earnings Yield | 9.374 |